Trade DiaMedica Therapeutics Inc. - DMAC CFD

Trading Conditions

• Type: CFD
• Spread: 0.0490
• Long position overnight funding adjustment: -0.02149%
• Short position overnight funding adjustment: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 7.0105
• Open: 6.8105
• 1-Year Change: 29.73%
• Day's Range: 6.6905 - 6.8305

What is DiaMedica Therapeutics Inc. (DMAC)?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel therapies for neurological and renal diseases. The company focuses on advancing treatments that target ischemic injury and inflammation, aiming to address conditions such as stroke and kidney disorders. DiaMedica employs a pipeline approach involving biologics and small molecules, with research and development activities centered on neuroprotection and tissue repair. Its work contributes to the broader field of regenerative medicine and therapeutic innovation.

DiaMedica Therapeutics Inc. Stock Price Today: Live Overview

The price today is shaped by market activity, with DiaMedica Therapeutics Inc. currently valued at $6.7995. Throughout the session, it has moved between $6.6405 and $6.9305, showing a daily change of -3.5763%.

FAQ: DiaMedica Therapeutics Inc. (DMAC)

What is the current price of DMAC stock?

DiaMedica Therapeutics Inc is currently priced at $6.7995.

Does DMAC pay dividends?

DiaMedica Therapeutics Inc does not pay dividends.

Does DMAC have a formal corporate presence or regional headquarters in the UAE?

DiaMedica Therapeutics Inc operates in the UAE via partners and distributors without an official regional office or subsidiary.

What is DMAC best known for?

DiaMedica Therapeutics Inc is most famous for developing therapies for neurological and kidney diseases.

What assets are typically shown together with DMAC?

Commonly shown alongside DMAC: Royalty Pharma plc, iShares Core MSCI EAFE ETF, TriplePoint Venture Growth BDC Corp